Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Lucentis (Ranibizumab) Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The lucentis (ranibizumab) market has witnessed robust expansion in recent years. Projections indicate it will advance from $3.74 million in 2025 to $3.96 million in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The historical progression of this market is attributable to clinical achievements in macular degeneration, a rise in diabetic retinopathy cases, the demographic shift towards an aging population, adoption among ophthalmologists, and regulatory approvals within eye care.
The market size for lucentis (ranibizumab) is anticipated to experience substantial growth over the next few years. It is projected to expand to $4.87 million in 2030, achieving a compound annual growth rate (CAGR) of 5.4%. This projected growth during the forecast period is attributable to an increase in the prevalence of retinal diseases, enhanced access to eye care services, the broadening of biosimilar competition, a rise in awareness for early diagnosis, and technological advancements in injection delivery. Significant trends identified for the forecast period include the sustained utilization of anti-VEGF therapies, an increase in the treatment of retinal vascular disorders, a rising preference for intravitreal injections, the expansion of ophthalmology specialty clinics, and a heightened focus on vision preservation.
Get A Free Sample Report With In-Depth Market Insights:
Lucentis (Ranibizumab) Market Development Factors: What’s Supporting Demand?
The growing occurrence of eye conditions is projected to stimulate the expansion of the Lucentis (ranibizumab) market moving forward. These conditions encompass a broad spectrum of diseases or ailments impacting the eyes, hindering their proper function. The increase in such disorders stems from factors like aging, genetic predispositions, unhealthy lifestyle choices including smoking and poor diet, and environmental influences like excessive sun exposure or prolonged digital screen usage. Lucentis functions by blocking vascular endothelial growth factor (VEGF), a protein that causes abnormal blood vessel growth and leakage in the retina, which is a primary contributor to conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). For illustration, the National Eye Institute, a US government agency, indicated in 2024 that 2.2 million Americans will be blind by 2030. Consequently, the rising frequency of eye-related disorders is propelling the growth of the Lucentis (ranibizumab) market. The increase in healthcare expenditure is anticipated to boost the Lucentis (ranibizumab) market’s progression moving forward. Healthcare spending represents the cumulative financial resources dedicated by individuals, governments, private insurers, and other bodies toward delivering healthcare services and goods. This surge in spending is attributed to factors like an aging demographic, innovations in medical technology, a higher incidence of chronic illnesses, and increased demand for healthcare provisions. Greater healthcare spending enhances the accessibility and availability of Lucentis (ranibizumab) by facilitating its widespread application in treating retinal diseases such as age-related macular degeneration and diabetic macular edema. It ensures that healthcare systems can allocate funds for its reimbursement, coverage, and distribution, ultimately leading to improved patient results and a reduction in the long-term impact of vision impairment. For example, the Office for National Statistics, a UK government department, reported in May 2024 that healthcare spending in the UK climbed by 5.6% between 2022 and 2023, compared to a 0.9% increase in 2022. The UK’s healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is fueling the growth of the Lucentis (ranibizumab) market.
Lucentis (Ranibizumab) Market Segment Trends And Revenue Contributors
The lucentis (ranibizumab) market covered in this report is segmented –
1) By Type: Single-use Prefilled Syringe, Single-use Glass Vial
2) By Application: Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Myopic Choroidal Neovascularization, Uveitis
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Lucentis (Ranibizumab) Market Transformation Trends: What Innovations Are Driving Change?
Leading companies active in the Lucentis (ranibizumab) market are concentrating on developing biosimilars to offer more cost-effective alternatives to the original branded product. Biosimilars are biological medical products that exhibit high similarity to an already approved reference biologic in terms of structure, effectiveness, and safety, with no clinically significant differences. For example, in April 2024, Formycon AG, a Germany-based biotechnology company, and Bioeq AG, a Switzerland-based biotechnology company, launched their biosimilar version of Lucentis (ranibizumab), identified as FYB201, in Canada and Switzerland. Health Canada granted marketing approval for the biosimilar as Ranopto, while Swiss Medic sanctioned it under the name Ranivisio. The authorization and subsequent introduction of FYB201 aim to present more economical treatment choices for individuals affected by retinal diseases. It functions by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that stimulates abnormal blood vessel development in the retina, which can result in swelling, leakage, and impaired vision.
Lucentis (Ranibizumab) Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG
View The Full Lucentis (Ranibizumab) Market Report:
Lucentis (Ranibizumab) Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the lucentis (ranibizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
